Guggenheim reiterates Buy on Pfizer stock ahead of earnings By Investing.com

Guggenheim reiterated a Buy on Pfizer with a $36 price target, implying 34% upside from the current $26.92 share price, while forecasting Q1 2026 EPS of $0.76 versus $0.72 consensus. The firm raised its Eliquis outlook and expects 2026 revenue/EPS of $61.3 billion and $3.00, modestly above consensus and near the top of management guidance. Investor focus remains on pipeline catalysts in 2026, including sigvotatug vedotin, obesity data at ADA, and mevrometostat, alongside Pfizer’s 6%+ dividend yield and ongoing litigation/contract developments.

Analysis

The market is still treating Pfizer like a slow-growth income staple, but the real setup is a hidden-duration trade: if Eliquis pricing is holding up better than feared, consensus 2026-2027 cash flow is too low, and that matters more than the quarter. The stock is effectively a leveraged call on whether the pipeline can bridge the patent cliff without a dividend reset or a multiple compression event; at a 6%+ yield, the downside is increasingly governed by income-holder behavior rather than near-term growth optics.

The second-order winner is Valneva, but only if the Lyme program can convert from headline efficacy into a partnerable asset with clean commercial economics. A positive readthrough there would also force investors to re-rate Pfizer’s BD discipline, because a successful vaccine asset would reinforce the value of external innovation versus pure internal R&D spend. Conversely, higher R&D at Pfizer is a near-term margin drag that may actually be bullish if it resets the narrative from ex-growth cash cow to pipeline reinvestment story, which is exactly how you avoid multiple compression into the patent-expiration window.

The market may be underestimating how asymmetric the stock becomes around the first meaningful obesity and oncology readouts in 1H/2H 2026. This is not a 1Q earnings trade; it is a six- to twelve-month catalyst stack where each incremental positive data point narrows the discount rate applied to the pipeline. The key risk is that one weak readout will be enough to make investors anchor on the 2026-2028 cliff again, causing a rapid de-rate because the current valuation already assumes the dividend is the floor.

Contrarian view: the stock does not need blockbuster pipeline success to work from here, only enough evidence that the post-cliff base business is larger than feared. If that is true, the current debate is misframed — upside comes from multiple expansion on durability, not from heroic earnings growth. The biggest miss in consensus is probably the optionality embedded in the dividend itself: for long-only holders, the yield creates a forced bid that can absorb mediocre fundamentals until a real negative catalyst appears.

Key Decisions for Investors

• Initiate a tactical long PFE position into earnings with a 3-6 month horizon; use the dividend yield as downside support, and size for modest upside because re-rating will likely come from guidance credibility rather than the print itself.
• Pair long PFE / short a basket of large-cap pharma with weaker cash return or worse patent-cliff visibility over the next 6-12 months; the relative trade should benefit if Pfizer’s Eliquis durability is validated and the market starts paying for pipeline optionality.
• Buy limited-risk upside in PFE via call spreads dated through the first half of 2026; the risk/reward improves if obesity or oncology data begins to de-risk the 2026-2028 cliff before the market fully prices it.
• Trade VALN as a catalyst proxy only on confirmed partnering or regulatory follow-through; otherwise avoid chasing the efficacy headline, because binary execution risk can erase the data-driven premium quickly.
• Use any post-earnings selloff in PFE toward the low-$20s as an entry for income-focused capital, but cut exposure if upcoming pipeline milestones start slipping in timing, since the stock’s support is narrative-dependent over a 6-9 month window.